Volume Growth Drives Acadia's Record Revenue in Q4 2025 as Leadership Shifts with New CEO

Strong Top-Line Performance Despite Higher Costs and One-Time Charges

Acadia Healthcare Company, Inc. posted fourth quarter revenue of $821.5 million, a 6.1% increase compared with the same period in 2024 and the highest quarterly figure in its history. The momentum was fueled by notable growth in acute inpatient psychiatry and an uptick in patient volumes across key facility types. This resilience came even as the company navigated rising expenses and an almost $1 billion non-cash goodwill impairment charge, which resulted in a net loss for the quarter.

Adjusted Earnings Impacted by Goodwill Impairment and PLGL Reserve

Despite the top-line strength, net results were heavily affected by a $996.2 million goodwill impairment charge and a $52.7 million adjustment to professional and general liability (PLGL) reserves. This led to a reported net loss attributable to Acadia of $(13.02) per diluted share for Q4 2025. Adjusted earnings per share, which exclude these and other non-cash or one-time items, were much lower year-over-year at $0.07 versus $0.64 in the prior year.

Patient Volume Growth and Network Expansion Stand Out

Q4 2025 saw patient days rise 3.1% year-over-year at same facilities, with revenue per patient day growing 1.3%. Admissions climbed 2.5%, showcasing solid demand in core markets. Acadia added 181 new licensed beds this quarter—including 144 beds from new facilities and 37 from expansions. For 2025 as a whole, 1,089 licensed beds were added to the network. The company continues to build out its footprint, now operating over 12,500 beds across 277 facilities in 40 states and Puerto Rico.

Expense Pressures: Wage Inflation, PLGL Reserves, and Settlement Costs

Total operating expenses in Q4 jumped 15%, mostly due to higher PLGL reserves (doubling year-over-year to $153 million at year end), ongoing wage pressures, and a $147 million legal settlements expense relating to securities litigation. Excluding PLGL and provider tax adjustments, expense growth was closer to 6%. Acadia’s cost structure continues to reflect the burden of opening new facilities (typically loss-making early on), annual wage increases, and legal/settlement activities. Interest expense also rose to $38 million, up from $30 million last year.

2026 Guidance Calls for Modest Growth and Strategic Discipline

For full-year 2026, management is targeting revenue of $3.37 to $3.45 billion, adjusted EBITDA of $575 to $610 million, and adjusted EPS of $1.30 to $1.55. Guidance is cautious, reflecting minimal to low-single-digit volume growth and enduring startup losses as new facilities ramp. Further headwinds are anticipated from Medicaid reimbursement changes and startup losses is forecasted at $47–53 million, down from $56 million in 2025.

Leadership Change: Debbie Osteen Returns as CEO to Reinforce Focus

Debbie Osteen, the company’s new Chief Executive Officer, stated her top priorities are steady leadership, operational discipline, and long-term positioning. Her leadership arrives at a pivotal time as Acadia works to balance robust patient demand with the realities of operating expenses and regulatory challenges.

Cash and Leverage Remain Manageable

As of December 31, 2025, Acadia reported $133.2 million in cash and $595 million available under its $1 billion revolving credit facility. Net leverage stood at 4.0x adjusted EBITDA, a level that the company believes is manageable given ongoing investment in new facilities and capacity expansion.

Key Takeaway: Growth Outpaces Headwinds, but Profit Recovery Hinges on Expense Control

Acadia heads into 2026 with demonstrably robust demand, a track record of network growth, and a newly appointed CEO committed to operational improvements. Pressures from wage inflation, legal liabilities, and Medicaid prescription changes remain, but guidance suggests the company expects steady improvement from new facility ramp and cost initiatives. Investors may want to watch closely for signs that operating discipline and volume expansion can translate into a return to margin growth as the year unfolds.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI